HOME >> BIOLOGY >> NEWS
Actonel significantly reduced moderate and severe vertebral fractures

San Antonio, TX (September 20, 2002) A new analysis of scientific data presented at today's meeting of the American Society for Bone and Mineral Research (ASBMR) showed that a 5 mg dose of Actonel (risedronate sodium tablets) daily significantly reduced moderate and severe vertebral fracture risk by 70 percent within one year in postmenopausal women with osteoporosis. Furthermore, the significant effect on vertebral fracture risk was sustained over three years.

This analysis combined data from two large Actonel clinical trials, VERT-NA and VERT-MN, which included postmenopausal women with either one prevalent vertebral fracture and low bone mineral density (BMD), or with at least two prevalent vertebral fractures. The objective of this analysis was to compare the incidence of moderate or severe vertebral fracture at one year in women who received Actonel or placebo. Fracture severity was determined using the fracture severity scoring system developed by Harry Genant, M.D., Professor of Radiology, Medicine, Epidemiology and Orthopaedic Surgery at the University of California, San Francisco, an investigator and pioneer of the assessment method used in the analysis.

Recent studies show severity of prevalent vertebral fractures is a predictor of future vertebral and non-vertebral fracture risk; patients with more severe baseline vertebral fractures are more likely to experience subsequent vertebral and non-vertebral fractures. Therefore, reducing the incidence of moderate or severe vertebral fractures may help decrease the risk of future fractures.

"The ultimate goal of osteoporosis treatment is to prevent fractures," said Dr. Genant, "These new findings, combined with previous Actonel clinical data showing reductions in both risk of first vertebral fracture and multiple vertebral fractures, suggest that Actonel reduces fracture risk across a range of osteoporotic severity."

According to
'"/>


20-Sep-2002


Page: 1 2 3 4

Related biology news :

1. Rare mutations can significantly increase risk factor for heart disease
2. Cancer health risk significantly underestimated by EPAs ambient model estimates
3. Double mastectomies significantly lower risk of breast cancer in women who are genetically at risk
4. HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma
5. ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis
6. Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function
7. Cognitive abilities increase significantly with time in most prematurely born children
8. Combining key ingredients of vegetarian diet cuts cholesterol significantly, says study
9. Pollen productionand allergiesmay rise significantly over next 50 years
10. Brain size in premature infants significantly smaller than full-term babies
11. Multicenter study shows Benecol spread significantly reduces cholesterol levels in patients taking statin drugs

Post Your Comments:
(Date:10/16/2014)... 2014) – Post-menopausal women experienced improvements in vaginal ... or genital bleeding, after 12 weeks of daily ... soy germ-based nutritional supplement previously shown to help ... peer-reviewed pilot study reported in a poster at ... meeting. , "These data documented improved vaginal ...
(Date:10/15/2014)... the pandemic risk from strains of influenza virus increases ... ourselves to become complacent that the most substantial threats ... , Influenza pandemics arise when a new virus strain ... immunity – spreads in the human population. There have ... the worst of which – the 1918 Spanish Flu ...
(Date:10/15/2014)... spreading rapidly and to an unexpected extent. The outbreak ... and the virus shows a new disease dynamic in ... this reason, the German National Academy of Sciences Leopoldina, ... and the Union of the German Academies of Sciences ... epidemic today. , In the statement the academies call ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
Cached News: